Personalized plans boost survival odds for older stem cell patients
NCT ID NCT05972577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physical function and quality of life. The goal was to see if these changes could help patients live longer and feel better after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>= 60 years * Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician * Must be able to understand written and spoken English * Must be willing to attend all study visits and comply with study procedures for the entire length of the study Exclusion Criteria: * Documented history of dementia * No possibility of proceeding to allogeneic hematopoietic cell transplant within the next 6 months as determined by treating physician * Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of enrollment * Inability or unwillingness to give written informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Platelet-Boosting drug help control a rare bone marrow disorder?
- Double-Drug attack on Hard-to-Treat lymphomas
- Can an HDAC inhibitor wipe out residual leukemia cells?
- PET scans guide Nivolumab-Chemo combo in relapsed hodgkin lymphoma
- Half-Matched stem cells tested as a cure for severe aplastic anemia
- Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?